EricLawrenceSmithMD

PubMed

• 3 citations
  Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma.
  David G Coffey, Francesco Maura, Edgar Gonzalez-Kozlova, J Javier Diaz-Mejia, Ping Luo, Yong Zhang, Yuexin Xu, Edus H Warren, Travis Dawson, Brian Lee, Hui Xie, Eric S...> ;Nature Communications. 2023 Sep 2
• The Future of Chimeric Antigen Receptor T Cell Therapy.
  Eric L Smith> ;Hematology/oncology Clinics of North America. 2023 Dec 1
• 9 citations
  Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma.
  Kai Rejeski, Michael D Jain, Eric L Smith> ;Transplantation and Cellular Therapy. 2023 Jul 1
• 1 citations
  Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort ...
  Neha Korde, Elizabet Tavitian, Donna Mastey, Joseph Lengfellner, Gil Hevroni, Andrew Zarski, Meghan Salcedo, Sham Mailankody, Hani Hassoun, Eric L Smith, Malin Hultcra...> ;Eclinicalmedicine. 2023 Mar 1
• 85 citations
  GPRC5D-Targeted CAR T Cells for Myeloma.
  Sham Mailankody, Sean M Devlin, Jonathan Landa, Karthik Nath, Claudia Diamonte, Elizabeth J Carstens, Douglas Russo, Romany Auclair, Lisa Fitzgerald, Briana Cadzin, Xi...> ;The New England Journal of Medicine. 2022 Sep 29
• 2 citations
  Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study.
  Sham Mailankody, Meghan Salcedo, Elizabet Tavitian, Miranda Burge, Neha Korde, Hani Hassoun, Alexander Lesokhin, Oscar Lahoud, Eric Smith, Malin Hultcrantz, Carlyn Tan...> ;Leukemia & Lymphoma. 2022 Nov 1
• 19 citations
  Activation of Tumor-Cell STING Primes NK-Cell Therapy.
  Erik H Knelson, Elena V Ivanova, Mubin Tarannum, Marco Campisi, Patrick H Lizotte, Matthew A Booker, Ismail Ozgenc, Moataz Noureddine, Brittany Meisenheimer, Minyue Ch...> ;Cancer Immunology Research. 2022 Aug 3
• Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.
  Sarah A Holstein, Fotis Asimakopoulos, Abdel Kareem Azab, Giada Bianchi, Manisha Bhutani, Leslie A Crews, Tom Cupedo, Hannah Giles, Sarah Gooding, Jens Hillengass, Luk...> ;Transplantation and Cellular Therapy. 2022 Aug 1
• 2 citations
  Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma.
  Malin Hultcrantz, Even H Rustad, Venkata Yellapantula, Allison Jacob, Theresia Akhlaghi, Neha Korde, Sham Mailankody, Alexander M Lesokhin, Hani Hassoun, Eric L Smith,...> ;Clinical Cancer Research. 2022 May 13
• 19 citations
  CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience.
  M Lia Palomba, David Qualls, Sebastien Monette, Shenon Sethi, Ahmet Dogan, Mikhail Roshal, Brigitte Senechal, Xiuyan Wang, Isabelle Rivière, Michel Sadelain, Renier J ...> ;Journal for Immunotherapy of Cancer. 2022 Feb 1
• 12 citations
  Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing.
  Xiuyan Wang, Oriana Borquez-Ojeda, Jolanta Stefanski, Fang Du, Jinrong Qu, Jagrutiben Chaudhari, Keyur Thummar, Mingzhu Zhu, Ling-bo Shen, Melanie Hall, Paridhi Gautam...> ;Molecular Therapy. Methods & Clinical Development. 2021 Jul 16
• 10 citations
  Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection.
  Leila Peraro, Christopher M. Bourne, Megan M. Dacek, Enver Akalin, Jae H. Park, Eric L. Smith, David A. Scheinberg> ;Molecular Therapy. 2021 Jul 2
• 3 citations
  Finding the optimal partner to pair with bispecific antibody therapy for multiple myeloma.
  Cedric Louvet, Omar Nadeem, Eric L Smith> ;Blood Cancer Discovery. 2021 Jul 1
• 36 citations
  Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.
  Benjamin Diamond, Neha Korde, Alexander M. Lesokhin, Eric L. Smith, Urvi A Shah, Sham Mailankody, Malin Hultcrantz, Hani Hassoun, Sydney X. Lu, Carlyn Tan, Even H Rust...> ;The Lancet. Haematology. 2021 Jun 1
• 7 citations
  Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m 2 ) in co...
  Neha Korde, Donna Mastey, Elizabet Tavitian, Sham Mailankody, Alexander M. Lesokhin, Hani Hassoun, Eric L. Smith, Nikoletta Lendvai, Malin Hultcrantz, Urvi A Shah, Car...> ;American Journal of Hematology. 2021 Mar 19
• Chimeric Antigen Receptor-Modified Immune Effector Cell Therapies: Learning From the Present; Charting a Path to the Future.
  Eric L. Smith, Renier J. Brentjens> ;Cancer Journal. 2021 Mar 1
• 6 citations
  Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.
  Marion Eveillard, Neha Korde, Amanda Ciardiello, Benjamin Diamond, Alexander M. Lesokhin, Sham Mailankody, Eric L. Smith, Hani Hassoun, Malin Hultcrantz, Urvi A Shah, ...> ;Clinica Chimica Acta; International Journal of Clinical Chemistry. 2021 Feb 2
• 19 citations
  Future of CAR T cells in multiple myeloma.
  Kitsada Wudhikarn, Sham Mailankody, Eric L. Smith> ;Hematology. American Society of Hematology. Education Program. 2020 Dec 4
• Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.
  Malin Hultcrantz, Joshua Richter, Cara A. Rosenbaum, Dhwani Patel, Eric L. Smith, Neha Korde, Sydney X. Lu, Sham Mailankody, Urvi A Shah, Alexander M. Lesokhin, Hani H...> ;Blood Cancer Discovery. 2020 Nov 4
• 1 citations
  Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma
  Alexandra Gomez-Arteaga, Gunjan L. Shah, Raymond E. Baser, Michael Scordo, Josel D. Ruiz, Adam Bryant, Parastoo B. Dahi, Arnab K. Ghosh, Oscar B Lahoud, Heather Landau...> ;Biology of Blood and Marrow Transplantation. 2020 Nov 1
• 94 citations
  Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma.
  Carlos Fernández de Larrea, Mette Staehr, Andrea V. Lopez, Khong Y. Ng, Yunxin Chen, William D. Godfrey, Terence J. Purdon, Vladimir Ponomarev, Hans-Guido Wendel, Reni...> ;Blood Cancer Discovery. 2020 Sep 1
• 23 citations
  COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers
  , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Medrxiv. 2020 Jun 11
• 16 citations
  Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
  Meghan Salcedo, Nikoletta Lendvai, Donna Mastey, Julia Schlossman, Malin Hultcrantz, Neha Korde, Sham Mailankody, Alexander M. Lesokhin, Hani Hassoun, Eric L. Smith, U...> ;Clinical Lymphoma, Myeloma & Leukemia. 2020 Mar 1
• 34 citations
  Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with m...
  Marion Eveillard, Even H Rustad, Mikhail Roshal, Yanming Zhang, Amanda Ciardiello, Neha Korde, Malin Hultcrantz, Sydney X. Lu, Urvi A Shah, Hani Hassoun, Eric L. Smith...> ;British Journal of Haematology. 2020 Feb 5
• 7 citations
  Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multipl...
  Adam Bryant, Patrick Hilden, Sergio Giralt, David J. Chung, Molly Maloy, Heather Landau, Ola Landgren, Michael Scordo, Gunjan L. Shah, Eric L. Smith, Richard J. O'Reil...> ;Biology of Blood and Marrow Transplantation. 2020 Jan 1
• Join now to see all

Abstracts/Posters

• Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
  Eric L Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients ...
  Eric L Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Optimal Dual-Targeted CAR Construct Simultaneously Targeting Bcma and GPRC5D Prevents Bcma-Escape Driven Relapse in Multiple Myeloma
  Eric L Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis
  Eric L Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy
  Eric L Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
  Eric L Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)
  Eric L Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
  Eric L Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all